Name
Primary cutaneous gamma-delta T-cell lymphoma (PCGD-TCL)
ICD-O-3 Morphology
9726/3: Primary cutaneous gamma delta T-cell lymphoma
Effective
2001 and later
Reportable
for cases diagnosed
1978 and later
Primary Site(s)
C440-C449
,
C490-C499
,
C510-C519
,
C600-C609
,
C632
Cutaneous (skin) lymphoma which presents with generalized skin lesions, mostly affecting the extremities (arms and legs).
Assign C449 if specific primary site cannot be determined.
See abstractor notes
Assign C449 if specific primary site cannot be determined.
See abstractor notes
Coding Manual:
Hematopoietic Coding Manual (PDF)
Abstractor Notes
PCGD-TCL manifests as single or generalized skin and subcutaneous lesions, occasionally with mucosal involvement, without preferential sites of involvement
Diagnostic Confirmation
This histology can be determined by positive histology (including peripheral blood) with or without genetics and/or immunophenotyping. Review the Definitive Diagnostic Methods, Immunophenotyping and Genetics Data sections below, and the instructions in the Hematopoietic Manual for further guidance on assigning Diagnostic confirmation.
Module Rule
None
Alternate Names
None
Definition
Primary cutaneous gamma-delta T-cell lymphoma (PCGD-TCL) is a clonal proliferation of mature, activated γδ T cells of the Vδ1 or Vδ2 subset, arising within the skin and subcutaneous tissues. (WHO 5th edition)
Definitive Diagnostic Methods
Cytogenetics
Genetic testing
Histologic confirmation
Immunohistochemistry
Immunophenotyping
Genetics Data
Immunophenotyping
CD2+ (expression/positive)
CD3+ (expression/positive)
CD5- (no expression/negative)
TCRγ+ (expression/positive)
TCRδ+ (expression/positive)
TCRβ− (no expression/positive)
Treatments
Chemotherapy
Radiation therapy
Transformations to
There are no known transformations
Transformations from
There are no known transformations
Same Primaries
Corresponding ICD-10 Codes (Cause of Death codes only)
C84.4 Peripheral T-cell lymphoma
Corresponding ICD-10-CM Codes (U.S. only)
C84.A_ Cutaneous T-cell lymphoma, unspecified (effective October 01, 2015)
C84.AA Cutaneous T-cell lymphoma, unspecified, in remission (effective October 01, 2024)
Signs and Symptoms
Diagnostic Exams
Blood chemistry studies
Bone marrow aspiration and biopsy
CT (CAT) scan
Flow cytometry
Immunohistochemistry
Immunophenotyping
PET (positron emission tomography) scan
Skin biopsy
Progression and Transformation
None
Epidemiology and Mortality
Incidence: 0.05 per million per years
Age: median age 63
Sex: male predilection
Survival: median survival of < 2 years
Sources
WHO Classification of Tumours Editorial Board. Haematolymphoid tumours. Lyon (France): International Agency for Research on Cancer; 2024. (WHO classification of tumours series, 5th ed.; vol. 11). https://publications.iarc.who.int/637.
Section: Mature T-cell and NK-cell neoplasms
Pages: Part B: 702-704
Section: Mature T-cell and NK-cell neoplasms
Pages: Part B: 702-704
International Classification of Diseases for Oncology, 3rd edition (including revisions). Geneva: World Health Organization, 2011, 2020.
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
PDQ® Adult Treatment Editorial Board. PDQ Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment. Bethesda, MD: National Cancer Institute. Updated <02/19/2025>. Available at: https://www.cancer.gov/types/lymphoma/hp/mycosis-fungoides-treatment-pdq. Accessed <03/31/2025>. [PMID: 2638928
Section: Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®)–Health Professional Version
Pages: https://www.cancer.gov/types/lymphoma/hp/mycosis-fungoides-treatment-pdq
Section: Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®)–Health Professional Version
Pages: https://www.cancer.gov/types/lymphoma/hp/mycosis-fungoides-treatment-pdq
Home